The Effects of Anesthetic Techniques and Palonosetron Administration on the Incidence of PONV
NCT ID: NCT02809378
Last Updated: 2017-07-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
150 participants
INTERVENTIONAL
2016-06-30
2017-04-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
It is reported that the maintenance of anesthesia with propofol-remifentanil or sevoflurane-propofol-remifentanil decreased the incidence of PONV compared sevoflurane alone, but failed to demonstrate the decreased incidence of PONV in 6-24 hr postoperative period in patients undergoing thyroidectomy. Administration of Palonosetron, newly developed 5-HT3 antagonists with long half life (48 hrs) may decrease the incidence of PONV particularly during this period.
The purpose of this study was to evaluate and compare the incidence of PONV after thyroidectomy with three different anesthetic methods, sevoflurane or sevoflurane-propofol-remifentanil or sevoflurane-propofol-remifentanil-palonosetron in woman patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Palonosetron Versus Combination of Palonosetron and Dexamethasone for Preventing Postoperative Vomiting in Patients Receiving Fentanyl by Patient-controlled Analgesia After Minor Orthopedic Surgery
NCT02744508
Effectiveness of Triple Therapy With Palonosetron for PON Prophylaxis
NCT02635828
Comparison of TIVA (Total Intravenous Anesthesia) and TIVA Plus Palonosetron in Preventing Postoperative Nausea and Vomiting
NCT01478165
Triple Therapy for Postoperative Nausea and Vomiting in Laparoscopic Gastrointestinal Surgery
NCT04853147
Continuous Infusion of Palonosetron for Preventing of Postoperative Nausea and Vomiting
NCT01482468
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sevoflurane
anesthesia induction with pentothal sodium (4-5 mg/kg), maintenance with sevoflurane(1.6-2.5 vol%)
sevoflurane
Inhalational anesthetics Halogenated.
pentothal sodium
intra-venous anesthetics for anesthesia induction
sevoflurane, remifentanil, and propofol
anesthesia induction and maintenance with remifentanil, propofol and sevoflurane(1.6-2.5 vol%)
sevoflurane
Inhalational anesthetics Halogenated.
remifentanil
ultra-short acting opioid anesthetics
propofol
intra-venous anesthetics for anesthesia induction and maintenance
Sevoflurane, remifentanil, propofol, and palonosetron
anesthesia induction and maintenance with remifentanil, propofol and sevoflurane(1.6-2.5 vol%), and palonosetron 75 ug administration prior to anesthesia induction.
Palonosetron
newly developed 5-HT3 antagonists with long half life (48 hrs) intravenous administration prior to anesthesia induction
sevoflurane
Inhalational anesthetics Halogenated.
remifentanil
ultra-short acting opioid anesthetics
propofol
intra-venous anesthetics for anesthesia induction and maintenance
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Palonosetron
newly developed 5-HT3 antagonists with long half life (48 hrs) intravenous administration prior to anesthesia induction
sevoflurane
Inhalational anesthetics Halogenated.
remifentanil
ultra-short acting opioid anesthetics
pentothal sodium
intra-venous anesthetics for anesthesia induction
propofol
intra-venous anesthetics for anesthesia induction and maintenance
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
20 Years
60 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
HK inno.N Corporation
INDUSTRY
Ajou University School of Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
DAE HEE KIM
Assistant Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dae Hee Kim, MD
Role: PRINCIPAL_INVESTIGATOR
Ajou University School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ajou universiry hospital
Suwon, Gyeonggi-do, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MED-CT4-15-461
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.